In vitro evaluation of the safe margin, antithrombotic and antiproliferative actions for the treatment of restenosis: Nitric oxide donor and polymers

Cell Biochemistry and Function

Volumn 29, Issue 3, 2011, Pages 207-214

  Sorragi, Cláudia de Lourdes ^a   Shishido, Silvia Mika ^a   Lemos, Maria Edwiges ^a   Marcondes, Sissi ^a   Antunes, Edson ^a   Krieger, Marta H ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antithrombotic; Nitric oxide donor; Restenosis; Stent

Indexed keywords

ANTICOAGULANT AGENT; BIOMATERIAL; NITRIC OXIDE DONOR; POLYMER; POLYVINYL ALCOHOL; POVIDONE; S NITROSOGLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AQUEOUS SOLUTION; ARTERY MUSCLE; ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; IN VITRO STUDY; INHIBITION KINETICS; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ANIMALS; BALB 3T3 CELLS; CELL PROLIFERATION; CORONARY RESTENOSIS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; DRUG-ELUTING STENTS; FIBRINOLYTIC AGENTS; HUMANS; MICE; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; NITRIC OXIDE DONORS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; POLYVINYL ALCOHOL; POVIDONE; RABBITS; S-NITROSOGLUTATHIONE;

ORYCTOLAGUS CUNICULUS;

EID: 79953691439     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1738     Document Type: Article

References (47)

1. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol 2006; 59: 232-239.
2. Burt HM, Hunter WL. Drug-eluting stents: a multidisciplinary success story. Adv Drug Deliv Rev 2006; 58: 350-357.
3. Fattori R, Piva T. Drug eluting stents in vascular intervention. Lancet 2003; 61: 247-249.
4. Colombo A, Srzewiecki J, Banning A, et al. Randomizes study to assess the effectiveness of slow- and moderate-release polymer-based placlitoxil-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794.
5. Pendyala L, Jabara R, Shinke T, et al. Drug-eluting stents: present and future. Cardiovasc Hematol Agents Med Chem 2008; 2: 105-115.
6. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drugelutingstents: part I. Circulation 2003; 107: 2274-2279.
7. Reynolds MM, Frost Meyerhoff ME. Nitric oxide-releasing hydrofobic polymers: preparation, characterization, and potential biomedical applications. Free Radic Biol Med 2004; 37: 926-936.
8. Takahashi H, Letourneur D, Grainger DW. Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules 2007; 8: 3281-3293.
9. Zucco F, de Angelis I, Testai I. Stammati A. Toxicology investigations with cell culture systems: 20 years after. Toxicol In Vitro 2004; 18: 153-163.
10. Boo J, de Hendriksen C. Reduction strategies in animal research: a review of scientific approaches at the intra-experimental, supra-experimental and extra-experimental levels. Altern Lab Anim 2005; 33: 369-377.
11. Carere A, Stammati A, Zucco F. In vitro toxicology methods: impact on regulation from technical and scientific advancements. Toxicol Lett 2002; 127: 153-160.
12. Shishido SM, Seabra AB, Loh W, Ganzarolli de Oliveira M. Thermal and photochemical nitric oxide release from S-nitrosothiols incorporated in Pluronic F127 gel: potential uses for local and controlled nitric oxide release. Biomaterials 2003; 20: 3543-3553.
13. Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribuition of cGMP-independent mechanisms. Biochem Biophys Res Commun 2000; 279: 412-419.
14. Irwin C, Roberts W, Naseem KM. Nitric oxide inhibits platelet adhesion to collagen through cGMP-dependent and independent mechanism: the potential role for S-nitrosilylation. Platelets 2009; 20: 478-486.
15. Askew SC, Butler AR, Flitney FW, Kemp GD, Megson IL. Chemical mechanisms underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione. Bioorg Med Chem 1995; 3: 1-9.
16. DeMerlis CC, Shoneker DR. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol 2003; 41: 319-326.
17. Wang Y-B, Lou Y, Luo Z-F, Zhang D-F, Wang Y-Z. Induction of apotosis and cell cycle arrest by polyvinylpyrrolidone K-30 and protective effect of α-tocopherol. Biochem Biophys Res Commun 2003; 308: 878-884.
18. Seabra AB, da Rocha LL, Eberlin MN, de Oliveira MG. Solid films of blended poly(vinyl alcohol)/poly(vinyl pyrrolidone) for topical S-nitrosoglutathione and nitric oxide release. J Pharm Sci 2005; 5: 994-1003.
19. Riden DR, Owen JS. Nitric oxide and platelet aggregation. Vitam Horm 1999; 57: 25-48.
20. Seabra AB, de Oliveira MG. Poly(vinyl alcohol) and poly(vinyl pyrrolidone) blended films for local nitric oxide release. Biomaterials 2004; 25: 3773-3782.
21. Buonassissi V, Venter JC. Hormone and neurotransmitter receptors in a established vascular endothelial cell line. Proc Natl Acad Sci 1976; 73, 1612-1616.
22. Janiszewski M, Lopes LR, Carmo AO, et al. 2005; Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. J Biol Chem 280: 40813-40819.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol 1983; 65: 55-63.
24. Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 1985; 24: 119-224.
25. 2 in the impairment of DNA replication and mitochondrial function. Free Radic Biol Med 1996; 20: 657-666.
26. Bellavite P, Andrioli G, Guzzo P, et al. A calorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994; 216: 444-450.
27. Hou Y, Wu X, Xie W, Braunschweiger PG, Wang P. The synthesis and cytotoxicity of fructose-1-SNAP, a novel fructose conjugated S-nitroso nitric oxide donor. Tetrahedron Lett 2001; 42: 825-829.
28. Babich H, Zuckerbraun HL. In vitro cytotoxicity of glyco-S-nitrosothiols: a novel class of nitric oxide donors. Toxicol In Vitro 2001; 15: 181-190.
29. Gasco A, Fruttero R, Rolando B. Focus on recent approaches for the development of new NO-donors. Mini Rev Med Chem 2005; 5: 217-229.
30. Dierickx PJ. Cytotoxicity of the MEIC reference chemical in rat hepatoma-derived Fa32 cells. Toxicology 2000; 150: 159-169.
31. Bell RM, Maddock HL, Yellon DM. The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. Cardiovasc Res 2003; 57: 405-415.
32. Li CQ, Wogan N. Nitric oxide as a modulator of apoptosis. Cancer Lett 2005; 226: 1-15.
33. Shishido SM, de Oliveira MG. Polyethylene glycol matrix reduces the rates of photochemical and thermal release of nitric oxide from S-nitroso-N-acetylcysteine. Photochem Photobiol 2000; 71: 273-280.
34. Ricardo KFS, Shishido SM, de Oliveira MG, Krieger MH. Characterization of the hypotensive effect of S-Nitroso-N-Acetyl-L-Cysteine (SNAC) in normotensive and hypertensive conscious rats. Nitric Oxide 2002; 7: 57-66.
35. Tullett JM, Rees DD, Shuker DEG, Gescher A. Lack of correlation between the observed stability and pharmacological properties of S-nitroso derivatives of glutathione and cysteine-related peptides. Biochem Pharmacol 2001; 62: 1239-1247.
36. Zhang Y, Hogg N. S-nitrosothiols: cellular formation and transport. Free Radic Biol Med 2005; 38: 831-838.
37. Costa RSA, Assreuy J. Multiple potassium channels mediate nitric oxide-induced inhibition of rat vascular smooth muscle cell proliferation. Nitric Oxide 2005; 13: 145-151.
38. Sarkar R, Godon D, Stanley JC, Webb RC. Dual cell cycle-specific mechanisms mediate the antimitogenic effects of nitric oxide in vascular smooth muscle cells. J Hypertens 1997; 15: 275-283.
39. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
40. Tung R, Kaul S, Diamond GA, et al. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med 2006; 144: 913-919.
41. Halkin A, Stone GW. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol 2004; 17: 271-282.
42. Hoenicka M, Schmid C. Cardiovascular effects of modulators of soluble guanylyl cyclase activity. Cardiovasc Hematol Agents Med Chem 2008; 6: 287-301.
43. Cardoso MHM, Morganti RP, Lilla S, et al. The role of superoxide anion in the inhibitory effect of SIN-1 in thrombin-activated human platelet adhesion. Eur J Pharmacol 2010; 627: 229-234.
44. Lowenstein CJ. Nitric oxide regulation of protein trafficking in the cardiovascular system. Cardiovasc Res 2007; 75: 240-246.
45. Roberts W, Riba R, Homer-Vanniasinkam S, Farndale RW, Naseem KM. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. Thromb Haemost 2008; 6: 2175-2185.
46. Gappa-Fahlenkamp H, Lewis RS. Improved hemocompatibility of poly(ethylene terephthalate) modified with various thiol-conatining groups. Biomaterials 2005; 26: 3479-3485.
47. Lima B, Forrester MT, Hess DT, Stamler JS. S-Nitrosylation in cardiovascular signaling. Circ Res 2010; 106: 633-646.